Perseon Launches INSPIRE 2017, a Dramatic Effort to Increase Adoption of Microwave Ablation to Fight Cancer

Published on:

SALT LAKE CITY, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN), today announced the launch of INSPIRE 2017, a new campaign which is dedicated to the growth and direction of the company over the next three years, particularly in the area of lung cancer, a disease where MicroThermX is better suited to treatment than other energy ablation products due to the system's 915 MHz frequency and synchronous wave alignment technology.

INSPIRE 2017 will reinforce the use of energy ablation in an industry where awareness is low, provide economic outcomes highlighting the impact of energy ablation, and continue to provide education to doctors and patients on the benefits of MicroThermX ablation technology.

In an effort to expand data supporting MicroThermX, Perseon is initiating five clinical studies in over 110 subjects as well as two non-clinical studies.

Additionally, the company is working to provide economic outcomes data via two separate initiatives. The first phase will be conducted with the assistance of current MicroThermX users and shared at an upcoming industry conference in early 2016. The second phase will provide a large scale economic model that will support the use of energy ablation.

"Perseon is generating momentum for energy ablation in an effort to raise the awareness of a technology that should be much more widely known and regarded due to its clinical outcomes and economic benefits,"

said Clint E. Carnell, President and CEO of Perseon. "INSPIRE 2017 is an extension of the company's ongoing engagement with the healthcare community, including physicians, healthcare systems, and patients, who are the reason we strive to continue developing cutting edge, life-saving technologies that fight cancer."

MicroThermX is an energy ablation system, which uses targeted microwave energy to treat cancer by ablating (burning) soft tissue with heat alone. Current treatment sites include cancers of the liver, kidney, bone, and lung. Perseon will continue to expand treatment targets to include other potential organs such as the pancreas, uterus, abdomen, and breast.

About Perseon Corporation
Perseon Corporation, formerly BSD Medical Corporation, invests its resources in fighting humanity's worst disease - cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy ablation solutions to healthcare providers and patients around the world. MicroThermX(R) treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.

About MicroThermX
Perseon's energy ablation system, MicroThermX, has been developed as a stand-alone therapy that employs precision-guided microwave energy to ablate (burn) and destroy soft tissue. Perseon has developed extensive intellectual property and has established distribution in the United States, Europe and Asia.

Treatment sites include tumor ablation of the liver, kidney, brain, bone, lung, and other soft-tissue locations.

Related Content

FDA says CT scans sometimes damage implantable cardiac electronic devices
Bilingual people have more efficient brains, imaging study shows
Use of AI opportunistic screening in CT for cardiovascular disease
ChatGPT is overly worried about ED patients
Low doses of radiation still increase risk of leukemia, lymphoma and myeloma
ACR offers resources to achieve radiology AI best practices

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.